Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

209.91USD
26 Sep 2017
Change (% chg)

$-1.70 (-0.80%)
Prev Close
$211.61
Open
$212.01
Day's High
$217.00
Day's Low
$208.55
Volume
2,768,383
Avg. Vol
2,207,819
52-wk High
$256.80
52-wk Low
$184.50

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.18
Market Cap(Mil.): $70,742.53
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.32

Financials

  Industry Sector
P/E (TTM): -- 30.47 15.77
EPS (TTM): -- -- --
ROI: -- 14.26 15.19
ROE: -- 15.57 13.80

Allergan boosts shares with $2 billion buyback

U.S. drugmaker Allergan Plc on Monday authorized a $2 billion buyback of its common stock, sending its shares up after a week of disappointing news on its drug development pipeline.

Sep 25 2017

UPDATE 2-Allergan boosts shares with $2 bln buyback

Sept 25 U.S. drugmaker Allergan Plc on Monday authorized a $2 billion buyback of its common stock, sending its shares up after a week of disappointing news on its drug development pipeline.

Sep 25 2017

BRIEF-Allergan board authorizes new $2 billion share repurchase program

* Allergan board of directors authorizes new $2 billion share repurchase program, affirms commitment to increasing cash dividend annually

Sep 25 2017

Allergan sets $2 bln share buyback; CFO to retire

Sept 25 U.S. drugmaker Allergan Plc on Monday authorized a $2 billion buyback of its shares and said its Chief Financial Officer Tessa Hilado would retire.

Sep 25 2017

BRIEF-Allergan Plc - CFO to retire

* Allergan announces Tessa Hilado, executive vice president and chief financial officer, to retire from company

Sep 25 2017

BRIEF-Allergan receives refusal to file letter from FDA for Vraylar SNDA

* Allergan receives refusal to file letter from FDA for Vraylar (Cariprazine) supplemental new drug application (SNDA) for the treatment of negative symptoms in Schizophrenia

Sep 22 2017

Native American tribe moves to dismiss Allergan patent case

A Native American tribe holding patents for drugmaker Allergan Plc on Friday moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

Sep 22 2017

Native American tribe moves to dismiss Allergan patent case

A Native American tribe holding patents for drugmaker Allergan Plc on Friday moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

Sep 22 2017

UPDATE 1-Native American tribe moves to dismiss Allergan patent case

Sept 22 A Native American tribe holding patents for drugmaker Allergan Plc on Friday moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

Sep 22 2017

Native American tribe moves to dismiss Allergan patent case

Sept 22 A Native American tribe holding patents for drugmaker Allergan Plc on Friday moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

Sep 22 2017

Earnings vs. Estimates